Have you ever heard of the term symphysis mandible? If not, don’t feel bad—it’s a relatively common but little-known condition. Symphysis mandible is a disorder that affects the temporomandibular joint (TMJ) which connects your jaw to your skull. It can cause pain, swelling, and difficulty moving your jaw. If you’ve been dealing with unexplained discomfort in your jaw or suddenly find yourself unable to open your mouth as widely as you used to, it may be time for you to get checked for a symphysis mandible. In this blog post, we'll discuss what a symphysis mandible is and how it can be treated.
Symphysis mandible is a type of joint that connects the left and right halves of the lower jaw (mandible). This joint is located in front of the ear canal, just below the zygomatic arch. The mandible is a U-shaped bone that forms the lower jaw and supports the teeth. It articulates with the temporal bones at the temporomandibular joints (TMJ).
There are two types of symphysis mandible – the true and false types. The true symphysis mandible is where the body of the mandible is joined to the tip of the chin by a fibrocartilaginous pad. The false symphysis mandible is where there is only a thin layer of connective tissue between the body and chin.
The Symphysis mandible is a type of joint that connects the left and right halves of the jawbone. This joint is located in front of the ear, where the temporal bones meet. The main function of the symphysis mandible is to allow for movement of the jaw, such as when you open and close your mouth.
There are both pros and cons to having this type of joint in your jaw. One pro is that it allows for a wide range of motion, which is necessary for eating and speaking. Another pro is that it provides stability to the jaw, helping to prevent displacement of the teeth.
However, there are also some cons to having a symphysis mandible. One con is that this type of joint can be susceptible to injury since there is a lot of movement at this point. Additionally, this type of joint can also arthritis or other degenerative conditions over time.
There are a few alternatives to the symphysis mandible. The first is the genioglossus advancement, which is when the front part of the tongue is moved forward. This can be done surgically or with an orthodontic appliance. Another alternative is maxillary advancement, which moves the whole upper jaw forward. This is also done surgically or with an orthodontic appliance. Lastly, there is bone grafting, which uses bone from another part of the body to build up the jawbone.
The Symphysis mandible is a joint that connects the two sides of your jaw. It provides stability and allows us to open up our mouths wide while eating, talking, or laughing. This joint can become weakened over time due to injury, dental problems, or even age-related degeneration.
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation